Fig. 5: Galangin 3-methyl ether (G3-ME) improves both cardiac function and structure in Tnnt2R109Q mice with pathological cardiac hypertrophy. | Acta Pharmacologica Sinica

Fig. 5: Galangin 3-methyl ether (G3-ME) improves both cardiac function and structure in Tnnt2R109Q mice with pathological cardiac hypertrophy.

From: Galangin 3-methyl ether alleviates mouse hypertrophic cardiomyopathy via targeting HDAC2 and subsequently inactivating the PI3K-AKT signaling pathway

Fig. 5: Galangin 3-methyl ether (G3-ME) improves both cardiac function and structure in Tnnt2R109Q mice with pathological cardiac hypertrophy.

a Schematic diagram of the mice experimental procedure. b The ratio of heart weight (HW) to tibial length (TL). c Representative images of echocardiograms. d Echocardiographic analysis of left ventricular (LV) anterior wall (LVAW) or posterior wall (LVPW) thickness in systolic and diastolic periods, and the ratio of E peak to A peak (E/A). n = 6 per group. e The serum NT-proBNP levels. n = 5 per group. f Representative images of cardiac H&E staining. g The cardiac cross-sectional area determined by H&E staining. n = 5 per group. h Representative images of the cardiac fibrosis area using Masson’s staining. i Quantification of fibrosis area by Masson’s staining. n = 5 per group. j Representative images of cardiomyocytes by WGA staining. k Analysis of cardiomyocyte size using WGA staining from 6 mice, with all cardiomyocytes in the same area analyzed in each section. n = 332, 348, 292, and 319, respectively. The values are mean ± SEM. *P < 0.05.

Back to article page